Efficacy and Safety of Ustekinumab Biosimilars in the Treatment of Moderate-to-Severe Plaque Psoriasis: A Systematic Review and Meta-analysis.
Mohsin Rashid, Awon Muhammad, Eeraj Saeed et al.
✦ AI-curated · Sources linked
In 30 seconds
This systematic review and meta-analysis evaluated the efficacy and safety of ustekinumab biosimilars in patients with moderate-to-severe plaque psoriasis. Analyzing data from nine randomized controlled trials involving 4,532 participants, the study found no statistically significant difference in the mean percent change in Psoriasis Area and Severity Index (PASI) at 12 weeks (MD 0.44, p = 0.54) between biosimilars and the reference product.
Key findings
- No significant difference in PASI at 12 weeks (MD 0.44, p = 0.54) between biosimilars and ustekinumab.
- Statistically significant differences in PASI and DLQI at 28 weeks, but not clinically meaningful.
- Pooled risk ratio for ADA development was 0.68 (95% CI 0.55-0.85; p = 0.0005), indicating lower ADA rates.
Why it matters
The findings support the use of ustekinumab biosimilars as a cost-effective alternative to the originator drug, potentially improving patient access to biologic therapies for psoriasis without compromising efficacy or safety.
What to keep in mind
The review is limited by the relatively short follow-up duration (≤ 52 weeks) and the industry funding of all included trials.